Publications & Presentations

Explore Iveric Bio’s pipeline, published articles, posters and presentations in geographic atrophy and beyond.

banner ribon

OUR PIPELINE

With a diverse portfolio of therapeutic candidates at different stages of development, Iveric Bio is focused on bringing innovative treatments for retinal diseases to those who need them most. Our pipeline includes our lead product candidate, avacincaptad pegol, which is being developed as a treatment for geographic atrophy (GA). Other candidates include IC-500 for GA, and AAV gene therapies for other retinal diseases.

EXPLORE OUR PIPELINE

PUBLISHED ARTICLES

Read published articles to learn more about the results of our clinical research on geographic atrophy and beyond.

Considerations on the Management of Macular Neovascularization in Patients with Geographic Atrophy Enrolled in Clinical Trials. Kaiser P, et al. Retina Today. 2022; March supplement:1-14.

View

Complement Cascade Inhibition in Geographic Atrophy: A Review. Desai D, Dugel PU. Eye. 2022;36:294-302.

View

Update on Avacincaptad Pegol for Geographic Atrophy. Ewing TM, et al. touch REVIEWS in Ophthalmology. 2022;16(1).

View

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Jaffe GJ, et al. Ophthalmology. 2021;128(4):576-586.

View

Clinical Impact of the GATHER1 Trial for Geographic Atrophy. Starr MR, Regillo CD. Retina Today. 2020; Fellows’ Focus:12-17.

View

POSTERS & PRESENTATIONS

View posters and presentations to learn more about our clinical research on geographic atrophy and beyond.

PRESENTATION

Khanani et al. The Efficacy of Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results. Retina Society 2022

view
PRESENTATION

Kaiser et al. Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results. Retina Society 2022

view
PRESENTATION

Mohammed Rafieetary. Avacincaptad Pegol for Geographic Atrophy. A Review of the GATHER1 and GATHER2 Clinical Trials. AAOpt 2022

view
PRESENTATION

Khanani et al. GATHER2 Pivotal Phase 3 Study Results: Efficacy of Intravitreal Avacincaptad Pegol in Geographic Atrophy. AAO 2022

view
PRESENTATION

Heier et al. GATHER2 Pivotal Phase 3 Study Results: Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy. AAO 2022

view
PRESENTATION

Lally et al. Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study. ASRS 2022

view
PRESENTATION

Jaffe et al. Evaluation of GA Growth Parameters and Impact on Foveal Progression: Post Hoc Analysis of the GATHER1 Trial. Angiogenesis 2022

view
PRESENTATION

Kaiser et al. Novel OCT Findings Regarding “Nascent GA at Risk” and Directionality of GA Progression in the GATHER1 Trial. Angiogenesis 2022

view
PRESENTATION

Lally et al. Nascent GA and Intermediate AMD Progression in the GATHER1 Clinical Trial: Post Hoc Analysis of 18-Month Data. AAO 2021

view
PRESENTATION

Danzig et al. Avacincaptad Pegol, a Novel C5 Inhibitor, Demonstrates a Continued Reduction in the Mean Rate of Geographic Atrophy Growth: 18-Month Results From the GATHER1 Clinical Trial. AAO 2021

view
PRESENTATION

Jaffe GJ, et al. Evaluation of GA Lesion Growth by Minimum Distance to the Fovea Center: Post Hoc Analysis of the GATHER1 Trial. RWC 2022

view
PRESENTATION

Ehlers JP, et al. Exploration of Machine Learning-Enhanced Compartmental Retinal Integrity Assessment for Progression Risk and Treatment Response in the GATHER1 Study. Macula Society 2022

view

Global CTA

Action